Ten years ago, every TRT protocol specified intramuscular (IM) injection — a 1–1.5 inch needle into the vastus lateralis (outer thigh), deltoid, or gluteal muscle. Today, a growing number of clinicians and patients use subcutaneous (SubQ) injection — a shorter needle (typically 27–30 gauge, 0.5 inch) into the fat layer of the abdomen or thigh. The evidence for this shift is real but nuanced.
The Evidence
Testosterone Levels
Multiple published studies have compared SubQ and IM testosterone cypionate injection. The findings are consistent: SubQ injection produces equivalent or slightly higher testosterone levels compared to IM at the same dose. A key study by Al-Futaisi et al. found that SubQ testosterone produced 14% higher total testosterone and 41% higher free testosterone compared to IM at equivalent doses.
The proposed explanation: subcutaneous fat has slower, more consistent absorption compared to the variable vascularity of muscle tissue. The result is a more gradual release with less peak-trough variation.
Estradiol
SubQ injection tends to produce slightly lower estradiol levels than IM at equivalent testosterone doses. The mechanism isn't fully understood, but the more gradual absorption may produce lower peak testosterone levels, which means less substrate for aromatase at any given moment. For men who struggle with elevated estradiol on IM injection, SubQ may offer a partial solution without dose reduction or aromatase inhibitors.
Hematocrit
Some data suggests SubQ injection produces less hematocrit elevation than IM. The evidence is mixed — not all studies confirm this — but the trend is plausible given the lower peak testosterone levels associated with SubQ delivery. For men at risk of polycythemia, SubQ may offer a modest advantage.
The Practical Differences
| Factor | Subcutaneous | Intramuscular |
|---|---|---|
| Needle size | 27–30 gauge, 0.5" (insulin syringe) | 22–25 gauge, 1–1.5" |
| Pain | Minimal — most men report little to no discomfort | Variable — PIP (post-injection pain) more common |
| Injection sites | Abdomen (peri-umbilical), outer thigh, love handles | Vastus lateralis (thigh), deltoid, ventrogluteal |
| Volume limit | 0.5–0.7 mL per site (practical limit) | Up to 3 mL per site |
| Absorption | Slower, more consistent | Faster, more variable |
| Patient preference | Generally preferred (smaller needle, less pain) | Traditional; some prefer the "certainty" of IM |
The Volume Limitation
The primary practical constraint on SubQ injection is volume. Most clinicians recommend no more than 0.5–0.7 mL per SubQ injection site to avoid post-injection lumps or discomfort. For men on higher doses (200mg/week of 200mg/mL concentration = 1 mL), SubQ requires either splitting the dose between two sites or using a higher-concentration formulation (250mg/mL).
For men on moderate doses (100–150mg/week) or those injecting twice weekly, the volume fits comfortably within SubQ parameters. This is one reason the SubQ trend has grown alongside the twice-weekly and daily microdosing protocols — the smaller per-injection volume makes SubQ practical.
What the Guidelines Say
The Endocrine Society and AUA guidelines still reference intramuscular injection as the standard route for testosterone cypionate/enanthate. Subcutaneous use is technically off-label — the FDA-approved route is IM. However, the clinical evidence supporting SubQ has grown substantial enough that many endocrinologists and men's health specialists now consider it a reasonable alternative, and several telehealth platforms have adopted SubQ as their default instruction.
SubQ vs. IM Decision Guide
- Choose SubQ if: You prefer minimal pain, your dose fits within 0.5 mL per site, you want potentially smoother testosterone levels, or you're managing estradiol issues
- Choose IM if: Your dose volume exceeds 0.7 mL per injection, you're comfortable with larger needles, or your prescriber specifically recommends IM for your protocol
- Either works: The evidence supports both routes producing adequate testosterone levels. The choice is primarily about comfort and practicality.
The Bottom Line
SubQ Works — And Most Men Prefer It
Subcutaneous testosterone injection produces equivalent or slightly better testosterone levels than intramuscular injection with less pain, smaller needles, and potentially smoother hormonal profiles. The volume limitation is the main practical constraint. For most TRT patients on standard doses, SubQ is a clinically supported alternative that improves the injection experience significantly.